Daiichi Sankyo Company, Limited (DSKYF)

Other OTC - Other OTC Delayed price. Currency in USD

Add to watchlist

35.11

-0.51

(-1.43%)

At close: 03:13PM EDT

Loading interactive chart…

Business Wire
ENHERTU® Demonstrated Statistically Significant and Clinically Meaningful Improvement in Progression-Free Survival in HR Positive, HER2 Low Metastatic Breast Cancer Following One or More Lines of Endocrine Therapy in DESTINY-Breast06 Phase 3 Trial
TOKYO & BASKING RIDGE, N.J., April 29, 2024--ENHERTU Showed Statistically Significant & Clinically Meaningful Improvement in PFS in HR Positive, HER2 Low mBC Following ET in DESTINY-Breast06
Yahoo Finance
AstraZeneca CEO on US-China tensions: 'We have established a very resilient supply chain'
AstraZeneca CEO Pascal Soriot joined Yahoo Finance to discuss the company's earnings today.
Zacks
Atossa (ATOS) Reports Positive Results From EVANGELINE Study
Atossa (ATOS) unveils positive results from its phase 2 EVANGELINE clinical study, which shows that (Z)-endoxifen can reduce the growth of ER+ breast cancer.